NCT04764344View on ClinicalTrials.gov

Haloperidol for the Treatment of Nausea and Vomiting in the ED

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

May 22, 2023

Study Completion Date

May 22, 2023

Conditions
VomitingNauseaAbdominal PainCannabis Use
Interventions
DRUG

Haloperidol

2.5mg of IV haloperidol will be diluted to 5ml with 0.9% NS and given over 2 minutes IVP

DRUG

Ondansetron

Ondansetron

Trial Locations (1)

49007

Bronson Methodist Hospital, Kalamazoo

All Listed Sponsors
lead

Western Michigan University School of Medicine

OTHER

NCT04764344 - Haloperidol for the Treatment of Nausea and Vomiting in the ED | Biotech Hunter | Biotech Hunter